ACRS — Aclaris Therapeutics Share Price
0.000.00%
Last trade - 00:00- $688.54m
- $583.13m
- $7.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.79 | ||
| Price to Tang. Book | 4.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 82.29 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -46.97% | ||
| Return on Equity | -48.42% | ||
| Operating Margin | -961.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.76 | 29.75 | 31.25 | 18.72 | 7.83 | 5.88 | 5.93 | 3.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Directors
- Christopher Molineaux NEC (55)
- Neal Walker PRE (51)
- Frank Ruffo CFO (55)
- David Gordon OTH (52)
- James Loerop OTH (57)
- Maxine Gowen IND (62)
- William Humphries IND (55)
- Anand Mehra IND (45)
- Vincent Milano IND (57)
- Andrew Powell IND (63)
- Bryan Reasons IND (53)
- Andrew Schiff IND (55)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- July 13th, 2012
- Public Since
- October 7th, 2015
- No. of Shareholders
- 46
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 139,663,680
- Address
- 701 Lee Road, Suite 103, WAYNE, 19087
- Web
- https://www.aclaristx.com/
- Phone
- +1 3026587581
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for ACRS
Aclaris Therapeutics Inc Annual Shareholders Meeting
Aclaris Therapeutics Inc Annual Shareholders Meeting
Q2 2026 Aclaris Therapeutics Inc Earnings Release
Similar to ACRS
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Aclaris Therapeutics share price?
As of Today at 19:04 UTC, shares in Aclaris Therapeutics are trading at $4.93. This share price information is delayed by 15 minutes.
How has the Aclaris Therapeutics share price performed this year?
Shares in Aclaris Therapeutics last closed at $4.93 and the price had moved by +276.34% over the past 365 days. In terms of relative price strength the Aclaris Therapeutics share price has outperformed the S&P500 Index by +187.88% over the past year.
What are the analyst and broker recommendations for Aclaris Therapeutics?
The overall consensus recommendation for Aclaris Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aclaris Therapeutics dividend yield?
Aclaris Therapeutics does not currently pay a dividend.
Does Aclaris Therapeutics pay a dividend?
Aclaris Therapeutics does not currently pay a dividend.
When does Aclaris Therapeutics next pay dividends?
Aclaris Therapeutics does not currently pay a dividend.
How do I buy Aclaris Therapeutics shares?
To buy shares in Aclaris Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aclaris Therapeutics?
As of the previous close price of $4.93, shares in Aclaris Therapeutics had a market capitalisation of $688.54m.
Where are Aclaris Therapeutics shares listed?
Here are the trading details for Aclaris Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACRS
What kind of share is Aclaris Therapeutics?
Based on an overall assessment of its quality, value and momentum Aclaris Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aclaris Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in Aclaris Therapeutics is $9.35. That is 89.66% above the last closing price of $4.93.
Analysts covering Aclaris Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.64 for the next financial year.
Find out moreWhat is the trend in the Aclaris Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aclaris Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +96.23%.
As of the last closing price of $4.93, shares in Aclaris Therapeutics were trading +73.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aclaris Therapeutics PE Ratio?
The Aclaris Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aclaris Therapeutics?
Aclaris Therapeutics' management team is headed by:
- Christopher Molineaux - NEC
- Neal Walker - PRE
- Frank Ruffo - CFO
- David Gordon - OTH
- James Loerop - OTH
- Maxine Gowen - IND
- William Humphries - IND
- Anand Mehra - IND
- Vincent Milano - IND
- Andrew Powell - IND
- Bryan Reasons - IND
- Andrew Schiff - IND